Eric R Siegel, MS

Research Program: Cancer Therapeutics Faculty Rank: Biostatistics Project Manager Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Biostatistics

Cancer Research Interest

• Disease Site Focus: No Specific Disease Site
• Research Focus Area: Treatment, Carcinogenesis, Diagnosis/ Prognosis, Health Disparities
• Type of Research: Translational, Population Sciences, Clinical
• Research Keywords: Data-mining administrative healthcare databases, Clinical Trials: design, management, and analysis, immunology, gene expression, proteomics, metabolomics, epidemiology
• Research Interest Statement: The following considerations make me unusually well-qualified for membership in the Cancer Institute: I have been practicing biostatistics at UAMS for 23 years. During this time, I have devoted roughly 75% of my time and effort collaborating with investigators at what is now the Winthrop P. Rockefeller Cancer Institute. I am the study statistician of record on 36 investigator-initiated clinical trials conducted at UAMS, 5 of which are currently enrolling and 2 of which are still active. I also have developed the statistical analysis plans and sample-size justifications for numerous animal studies conducted by Cancer Institute investigators. I regularly lend both my statistical expertise and my critical-reading and editing skills to the preparation of grant applications by Cancer Institute faculty to external funding agencies. My efforts here have led to me receiving salary support from 45 cancer-related grants awarded by the NIH, the Department of Defense, the Veterans Administration, and the Arkansas Breast Cancer Research Program over the past 23 years. Seven of those cancer-related grants currently provide on-going salary support. As of March 7, 2023, I have co-authored 199 peer-reviewed publications since coming to UAMS. Fully 135 of them are cancer-related. They range in scope from bench to bedside to nationwide, i.e., from the basic sciences to clinical trials to large observational studies that utilize federal-government databases. In two cases where the investigator left UAMS for greener pastures, I have maintained productive collaborations with them. For example, I have co-authored 21 publications thus far with Alessandro Santin, MD, 14 of which were written after he moved to Yale University. I continue to this day to help Dr. Santin prepare grant applications to the National Cancer Institute, which, if funded, would lead to UAMS subcontracts with Yale as the pass-through agency. I also have co-authored 13 publications thus far with Yi-Hong Zhou, PhD, 8 of which were written after she moved to University of California, Irvine. This collaboration has also resulted in several grant applications (with UAMS subcontracts) submitted by Dr. Zhou to the National Cancer Institute. I have a long history of cancer-related service activity that continues to this day. Since 2005, I have been a participating member of what then was called the Gastrointestinal Malignancy Study Group (GIMSG), and now is called the Gastrointestinal Disease-oriented Committee (GI DOC). In 2011, I joined the newly formed Head-and-Neck Disease-oriented Committee (H&N DOC). Both DOCs routinely receive protocols of clinical trials to review and discuss for whether the Cancer Institute should try to open them here. When this happens, I review the protocols for statistical soundness, and verbally tell the DOCs my findings. In 2021, I joined the Protocol Review and Monitoring Committee (PRMC) as one of three statistical reviewers. In that capacity, I review up to 3 protocols a month for statistical soundness, and I write detailed written reviews of their strengths and weaknesses. When taken together, these considerations demonstrate that I have a long and productive record of contribution to the fight against cancer. That is why I am unusually well-qualified for membership in the Cancer Institute.

Contact Information

• Email Address: SIEGELERICR@UAMS.EDU

Active Grants

• NIH/Nat. Cancer Institute – 1U54CA272691
  “Project 1 – Prevention of MGUS progression to MM by modulating the bone marrow microenvironment ”
  Co-Investigator
  09/01/23 – 08/31/27
• NIH/Nat. Cancer Institute – 1R01CA245083
  “Improvement of cellular immunotherapy during dysbiosis”
  Co-Investigator
  09/15/21 – 08/31/26

Publications

• Mathews CG, Stambough JB, Stronach B, [et al., including Siegel ER]. Successful Transition to Same Calendar Day Discharge in Total Joint Arthroplasty at an Academic Center. Arthroplasty today. 2024 27:101354. PMID: 38524150. PMCID: PMC10958211.
• Bellone S, Jeong K, Halle MK, [et al., including Siegel ER]. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings of the National Academy of Sciences of the United States of America. 2024 121(17):e2321898121. PMID: 38625939.
• Bolin EH, Escalona-Vargas D, Siegel ER, [et al.]. Feasibility of magnetoencephalography in fetuses with cyanotic congenital heart disease. Prenatal diagnosis. 2024. PMID: 38622756.
• Sheth SS, Oh JE, Bellone S, [et al., including Siegel ER]. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical cancer research : an official journal of the American Association for Cancer Research. 2024:OF1-OF10. PMID: 38592381.
• Guo W, Strouse C, Mery D, [et al., including Siegel ER]. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation. Cancers. 2024 16(6). PMID: 38539451. PMCID: PMC10969019.
• Roque DM, Siegel ER, Buza N, [et al.]. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British journal of cancer. 2024. PMID: 38438590. PMCID: PMC10951353.
• Mercado L, Rose S, Escalona-Vargas D, [et al., including Siegel ER]. Correlation of fetal heart rate dynamics to inflammatory markers and brain-derived neurotrophic factor during pregnancy. Journal of perinatal medicine. 2024. PMID: 38404246.
• Edington MR, Stronach BM, Barnes CL, [et al., including Siegel ER]. Do Quality Measures or Hospital Characteristics Predict Readmission Penalties for Hip and Knee Arthroplasty?. The Journal of arthroplasty. 2024. PMID: 38401618.
• Otwell AG, Stambough JB, Cherney SM, [et al., including Siegel ER]. Does the type of lower extremity fracture affect long-term opioid usage? A meta-analysis. Archives of orthopaedic and trauma surgery. 2024. PMID: 38366036.
• Guo W, Zhan Y, Mery D, [et al., including Siegel ER]. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood cancer journal. 2024 14(1):30. PMID: 38355688. PMCID: PMC10866867.
• Siebenmorgen JP, Goree JH, Siegel ER, [et al.]. Hospital-Wide Adherence to Postsurgical Opioid Prescribing Guidelines: A Retrospective Cohort Study. The Journal of surgical research. 2024 296:571-580. PMID: 38340491.
• Bellone S, Siegel ER, Scheim DE, Santin AD. Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID. Gynecologic oncology reports. 2024 51:101324. PMID: 38273933. PMCID: PMC10809113.
• Sun F, Cheng Y, Wanchai V, [et al., including Siegel E]. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nature communications. 2024 15(1):615. PMID: 38242888. PMCID: PMC10798961.
• Potter GR, Feuchtenberger BW, Sowinski HN, [et al., including Siegel ER]. How Many Patients Qualify for Extended Oral Antibiotic Prophylaxis Infection Following Primary and Revision Hip and Knee Arthroplasties?. The journal of knee surgery. 2023. PMID: 38101450.
• Bellone S, Siegel EE, Santin AD. Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID. Gynecologic oncology reports. 2023 50:101301. PMID: 38029227. PMCID: PMC10654147.
• Abraham TH, Miller Robinson C, Siegel ER, Cornett LE. Using Focused Ethnography to Inform Biomedical Research Infrastructure Enhancement At Primarily Undergraduate Institutions in Arkansas. Advances in physiology education. 2023. PMID: 37883733.
• Mercado L, Escalona-Vargas D, Siegel ER, [et al.]. Exploring the Influence of Fetal Sex on Heart Rate Dynamics Using Fetal Magnetocardiographic Recordings. Reproductive sciences (Thousand Oaks, Calif.). 2023. PMID: 37884730.
• Sustich SJ, Stambough JB, Hui R, [et al., including Siegel ER]. Postoperative Opioid Consumption is Greater after Simultaneous versus Staged Bilateral Total Knee Arthroplasty. The journal of knee surgery. 2023. PMID: 37852291.
• Cheng Y, Sun F, Alapat DV, [et al., including Siegel ER]. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell reports. Medicine. 2023 4(10):101214. PMID: 37794587. PMCID: PMC10591052.
• Mutlu L, Manavella DD, Bellone S, [et al., including Siegel ER]. In vivo and in vitro efficacy of trastuzumab deruxtecan in uterine serous carcinoma. Molecular cancer therapeutics. 2023. PMID: 37676984.
• Morehead LC, Garg S, Wallis KF, [et al., including Siegel ER]. Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine Restriction in a Colorectal Cancer Model. Cancers. 2023 15(18). PMID: 37760436. PMCID: PMC10526448.
• Glenn GT, Apple AE, Mears SC, [et al., including Siegel ER]. Articulating Hip Spacers with a Constrained Acetabular Liner: Effect of Acetabular Bone Loss and Cementation Quality. Antibiotics (Basel, Switzerland). 2023 12(9). PMID: 37760681. PMCID: PMC10526049.
• Sun F, Cheng Y, Ying J, [et al., including Siegel ER]. A gene signature can predict risk of MGUS progressing to multiple myeloma. Journal of hematology & oncology. 2023 16(1):70. PMID: 37386588. PMCID: PMC10308756.
• Bellone S, McNamara B, Mutlu L, [et al., including Siegel ER]. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers. International journal of molecular sciences. 2023 24(10). PMID: 37240216. PMCID: PMC10219151.
• Mercado L, Escalona-Vargas D, Blossom S, [et al., including Siegel ER]. The effect of maternal pregestational diabetes on fetal autonomic nervous system. Physiological reports. 2023 11(9):e15680. PMID: 37144450. PMCID: PMC10161040.
• Nounamo B, Jousheghany F, Siegel ER, [et al.]. VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen. International journal of molecular sciences. 2023 24(3). PMID: 36768830. PMCID: PMC9917008.
• Mehl ST, Simmons PM, Whittington JR, [et al., including Siegel ER]. Assessing uterine electrophysiology prior to elective term induction of labor. Current research in physiology. 2023 6:100103. PMID: 37554388. PMCID: PMC10404855.
• Cooper KB, Lee AK, Tucker DW, [et al., including Siegel E]. Severity of Covid-19 Lockdown Orders Corresponds to Orthopaedic Trauma Volume. Journal of surgical orthopaedic advances. 2022 31(4):222-225. PMID: 36594977.
• Baltz AP, Siegel ER, Kamal AH, [et al.]. Clinical Impact of ASCO Choosing Wisely Guidelines on Staging Imaging for Early-Stage Breast Cancers: A Time Series Analysis Using SEER-Medicare Data. JCO oncology practice. 2022:OP2200500. PMID: 36375114. PMCID: PMC9970287.
• Jules A, Means D, Troncoso JR, [et al., including Siegel ER]. Diffuse Reflectance Spectroscopy of Changes in Tumor Microenvironment in Response to Different Doses of Radiation. Radiation research. 2022. PMID: 36240754. PMCID: PMC9798304.
• Cooper KB, Mears SC, Siegel ER, [et al.]. The Hip and Femur Fracture Bundle: Preliminary Findings From a Tertiary Hospital. The Journal of arthroplasty. 2022 37(8S):S761-S765. PMID: 35314286.
• Norris AC, Mears SC, Siegel ER, [et al.]. Social Needs of Patients Undergoing Total Joint Arthroplasty. The Journal of arthroplasty. 2022 37(7S):S416-S421. PMID: 35197200. PMCID: PMC9454235.
• Roque DM, Siegel ER, Buza N, [et al.]. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British journal of cancer. 2022 126(12):1695-1703. PMID: 35149854. PMCID: PMC8853032.
• O'Brien PE, Mears SC, Siegel ER, [et al.]. Does In-Hospital Opioid Use Affect Opioid Consumption After Total Joint Arthroplasty?. The Journal of arthroplasty. 2022 37(5):824-830. PMID: 35114319.
• Smithson KB, Parham SG, Mears SC, [et al., including Siegel ER]. Transfers of pediatric patients with isolated injuries to a rural Level 1 Orthopedic Trauma Center in the United States: are they all necessary?. Archives of orthopaedic and trauma surgery. 2022 142(4):625-631. PMID: 33394179.
• Kaufmann Y, Byrum SD, Acott AA, [et al., including Siegel ER]. Proteomic profiling of tear fluid as a promising non-invasive screening test for colon cancer. American journal of surgery. 2022. PMID: 35354531.
• Bellone S, Roque DM, Siegel ER, [et al.]. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer. 2022 128(6):1206-1218. PMID: 34875107. PMCID: PMC9465822.
• Escalona-Vargas D, Siegel ER, Oliphant S, Eswaran H. Evaluation of Pelvic Floor Muscles in Pregnancy and Postpartum With Non-Invasive Magnetomyography. IEEE journal of translational engineering in health and medicine. 2022 10:1800106. PMID: 34950538. PMCID: PMC8673696.
• Makhoul I, Ibrahim SM, Abu-Rmaileh M, [et al., including Siegel ER]. P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses. Oncotarget. 2021 12(22):2252-2265. PMID: 34733416. PMCID: PMC8555684.
• Tymon-Rosario J, Siegel ER, Bellone S, [et al.]. Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. Gynecologic oncology. 2021 163(1):93-99. PMID: 34372971. PMCID: PMC8721852.
• Cooper KB, Siegel ER, Stambough JB, [et al.]. The Alpha-Defensin Prosthetic Joint Infection Test Has Poor Validity for Native Knee Joint Infection. The Journal of arthroplasty. 2021 36(8):2957-2961. PMID: 33896668.
• Bellone S, Roque DM, Siegel ER, [et al.]. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals of oncology : official journal of the European Society for Medical Oncology. 2021 32(8):1045-1046. PMID: 33932502. PMCID: PMC9465821.
• Stambough JB, Hui R, Siegel ER, [et al.]. Narcotic Refills and Patient Satisfaction With Pain Control After Total Joint Arthroplasty. The Journal of arthroplasty. 2021 36(2):454-461. PMID: 32839063. PMCID: PMC7855659.
• Eswaran H, Lau C, Murphy P, [et al., including Siegel ER]. Tracking evoked responses to auditory and visual stimuli in fetuses exposed to maternal high-risk conditions. Developmental psychobiology. 2021 63(1):5-15. PMID: 32654120. PMCID: PMC7875520.
• Escalona-Vargas D, Bolin EH, Lowery CL, [et al., including Siegel ER]. Recording and quantifying fetal magnetocardiography signals using a flexible array of optically-pumped magnetometers. Physiological measurement. 2021 41(12):125003. PMID: 33086201. PMCID: PMC7875519.
• Dadgar S, Troncoso JR, Siegel ER, [et al.]. Spectroscopic investigation of radiation-induced reoxygenation in radiation-resistant tumors. Neoplasia (New York, N.Y.). 2020 23(1):49-57. PMID: 33220616. PMCID: PMC7683290.
• Han M, Watts JA, Jamshidi-Parsian A, [et al., including Siegel ER]. In Vivo Lymphatic Circulating Tumor Cells and Progression of Metastatic Disease. Cancers. 2020 12(10). PMID: 33028044. PMCID: PMC7650582.
• Ramos JC, Sparano JA, Chadburn A, [et al., including Siegel ER]. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood. 2020 136(11):1284-1297. PMID: 32430507. PMCID: PMC7483436.
• Avci R, Whittington JR, Blossom SJ, [et al., including Siegel ER]. Studying the Effect of Maternal Pregestational Diabetes on Fetal Neurodevelopment Using Magnetoencephalography. Clinical EEG and neuroscience. 2020 51(5):331-338. PMID: 32157908. PMCID: PMC8232045.
• Han M, Watts JA, Jamshidi-Parsian A, [et al., including Siegel ER]. Lymph Liquid Biopsy for Detection of Cancer Stem Cells. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2020. PMID: 32869909. PMCID: PMC9237844.
• Fader AN, Roque DM, Siegel E, [et al.]. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 26(15):3928-3935. PMID: 32601075. PMCID: PMC8792803.
• Ke C, Luo JR, Cen ZW, [et al., including Siegel ER]. Dual antivascular function of human fibulin-3 variant, a potential new drug discovery strategy for glioblastoma. Cancer science. 2020 111(3):940-950. PMID: 31922633. PMCID: PMC7060460.
• Goodson KM, Kee JR, Edwards PK, [et al., including Siegel ER]. Streamlining Hospital Treatment of Prosthetic Joint Infection. The Journal of arthroplasty. 2020 35(3S):S63-S68. PMID: 32046835.
• Shnaekel AW, Kee JR, Travis KE, [et al., including Siegel ER]. The Atypical Patient With Slipped Capital Femoral Epiphyses May Be at Increased Risk for a Missed Contralateral Slip. Orthopedics. 2020 43(2):e114-e118. PMID: 31930409.
• Todorova VK, Siegel ER, Kaufmann Y, [et al.]. Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model. Translational oncology. 2020 13(2):471-480. PMID: 31918212. PMCID: PMC7031101.
• Pabona JMP, Burnett AF, Brown DM, [et al., including Siegel ER]. Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells. Reproductive sciences (Thousand Oaks, Calif.). 2020 27(1):267-277. PMID: 32046384. PMCID: PMC7077930.
• Hsu PC, Kadlubar SA, Siegel ER, [et al.]. Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer. PloS one. 2020 15(4):e0230248. PMID: 32298288. PMCID: PMC7162481.
• Hernandez Puente CV, Hsu PC, Rogers LJ, [et al., including Siegel E]. Association of DNA-Methylation Profiles With Immune Responses Elicited in Breast Cancer Patients Immunized With a Carbohydrate-Mimicking Peptide: A Pilot Study. Frontiers in oncology. 2020 10:879. PMID: 32582547. PMCID: PMC7290046.
• Behrens A, Jousheghany F, Yao-Borengasser A, [et al., including Siegel ER]. Carbohydrate (Chondroitin 4) Sulfotransferase-11-Mediated Induction of Epithelial-Mesenchymal Transition and Generation of Cancer Stem Cells. Pharmacology. 2020 105(5-6):246-259. PMID: 32344408.
• Niepel D, Krishna B, Siegel ER, [et al.]. A pilot study: Auditory steady-state responses (ASSR) can be measured in human fetuses using fetal magnetoencephalography (fMEG). PloS one. 2020 15(7):e0235310. PMID: 32697776. PMCID: PMC7375519.
• Jenkins SV, Robeson MS 2nd, Griffin RJ, [et al., including Siegel ER]. Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking. Cancer research. 2019 79(23):5999-6009. PMID: 31591154. PMCID: PMC6891208.
• Bolin EH, Escalona-Vargas D, Daily JA, [et al., including Siegel ER]. Magnetocardiographic identification of prolonged fetal corrected QT interval in women receiving treatment for opioid use disorder. The journal of obstetrics and gynaecology research. 2019 45(10):1989-1996. PMID: 31297963.
• Mathews CS, Dua K, Cole A, [et al., including Siegel E]. Prevalence of Ulnar Artery Thrombosis in Orthopedic Surgeons. Orthopedics. 2019 42(5):e415-e422. PMID: 31185121.
• Liu JJ, Rosson TB, Xie JJ, [et al., including Siegel E]. Personalized Inflammatory Bowel Disease Care Reduced Hospitalizations. Digestive diseases and sciences. 2019 64(7):1809-1814. PMID: 30746632.
• Galanzha EI, Menyaev YA, Yadem AC, [et al., including Siegel ER]. In vivo liquid biopsy using Cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma. Science translational medicine. 2019 11(496). PMID: 31189720. PMCID: PMC9235419.